This application proposes the fourth renewal of the UNC Breast Cancer SPORE. Originally funded in 1992, the UNC SPORE has used significant institutional investment and the distinctive SPORE elements: funding flexibility, interdisciplinary collaboration, bidirectional translational research, developmental programs, and interSPORE partners to build an outstanding program in translational breast cancer research. The UNC SPORE'S combination of population-based research, molecular genetics, breast cancer biology, health disparities research, tissue-acquiring clinical trials, database development, and expertise in bioinformatics and biostatistics was made possible with long-term SPORE support. Interaction between disciplines has resulted in substantial productivity, as measured by important findings published in high impact journals, career advancement for junior investigators, developmental research leading to grants and new SPORE projects, multiple funded interSPORE collaborations, and innovative approaches to breast cancer etiology, classification, prognosis, and therapy. Our projects are conceptually linked by studies of breast cancer molecular intrinsic subtypes, particularly the triple negative breast cancers, basal-like cancer and a newly-defined subtype, Claudin low. We feature a nation leading population science study of breast cancer and minority disparities, the Carolina Breast Cancer Study (CBCS), entering its 20th year of SPORE funding. Our molecular genetics translational group is developing new technology for intrinsic subtyping with which to analyze clinically-annotated samples from CBCS and local, national, and international trials. Novel translational studies of gene expression, tumor microevironment and a systems approach to the kinome will utilize both preclinical models and human tumors. The projects are entitled: 1) Carolina Breast Cancer Study: Genomic and epidemiologic determinants of breast cancer minority disparities. 2) Targeting the infiltrating immune cells in Claudin-low tumors. 3) Development and validation of predictive markers for triple negative breast cancers. 4) Stromal response subtypes in breast cancer risk and progression 5) Quantitative proteomic analysis of the human kinome in Claudin-low and basal-like breast cancer Five of the co-Project leaders are products of the SPORE career development program. Two of the projects resulted from our SPORE Developmental Research Program. The SPORE is supported by exceptional infrastructure and institutional commitment from the UNC Lineberger Comprehensive Cancer Center and three SPORE-funded cores: Pathology, Genomics, Biostatistics &Bioinformatics, and Administration.

Public Health Relevance

The UNC Breast Cancer SPORE contributes to the clinical application of molecular subtyping to breast cancer discovery, prognostication, conduct of clinical trials, and understanding of minority disparities in breast cancer. Our projects continue to explore the effect of intrinsic subtype on the predisposition, progression, and therapeutic resistance of difficult-to-treat breast cancers. UNO SPORE's technology development, population-based studies, and analysis of clinical trials will have substantial translational impact.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058223-19A1
Application #
8335628
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (M1))
Program Officer
Kuzmin, Igor A
Project Start
1997-08-05
Project End
2017-08-31
Budget Start
2012-09-14
Budget End
2013-08-31
Support Year
19
Fiscal Year
2012
Total Cost
$1,933,963
Indirect Cost
$659,514
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
McRee, Autumn J; Marcom, Paul K; Moore, Dominic T et al. (2018) A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clin Breast Cancer 18:289-297
DeBono, Nathan L; Robinson, Whitney R; Lund, Jennifer L et al. (2018) Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. J Womens Health (Larchmt) 27:377-386
Nasarre, Patrick; Bonilla, Ingrid V; Metcalf, John S et al. (2018) TRAF3-interacting protein 3, a new oncotarget, promotes tumor growth in melanoma. Melanoma Res 28:185-194
Pearce, Oliver M T; Delaine-Smith, Robin M; Maniati, Eleni et al. (2018) Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. Cancer Discov 8:304-319
Williams, Lindsay A; Nichols, Hazel B; Hoadley, Katherine A et al. (2018) Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. Cancer Causes Control 29:25-32
Couture, Heather D; Williams, Lindsay A; Geradts, Joseph et al. (2018) Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype. NPJ Breast Cancer 4:30
Lei, Jonathan T; Shao, Jieya; Zhang, Jin et al. (2018) Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep 24:1434-1444.e7
Troester, Melissa A; Sun, Xuezheng; Allott, Emma H et al. (2018) Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst 110:
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12

Showing the most recent 10 out of 598 publications